




PHARMACEUTICAL 2022

Integrated
BioPharma, Inc.

INTEGRATED BIOPHARMA INC
Rank 174 of 466





RealRate

PHARMACEUTICAL 2022

INTEGRATED BIOPHARMA INC Rank 174 of 466

Integrated
BioPharma, Inc.

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 294% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 284% points.

The company's Economic Capital Ratio, given in the ranking table, is 179%, being 101% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	17,998
Cost of Goods Sold	54,079
Intangible Assets	0
Liabilities, Current	9,236
Liabilities, Non-Current	1,870
Other Assets	5,700
Other Compr. Net Income	0
Other Expenses	-766
Other Liabilities	0
Other Net Income	1,463
Other Revenues	63,559
Property and Equipment	1,742
Research and Development	0
Selling, General and Administrative Expense	3,696

Output Variable	Value in 1000 USD
Assets	25,440
Liabilities	11,106
Expenses	57,009
Revenues	63,559
Stockholders Equity	14,334
Net Income	8,013
Comprehensive Net Income	8,013
Economic Capital Ratio	179%